Moderna, Inc. — Director's Dealing 2020

Mar 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-03-16

Reporting Person: Kim Lorence H. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-16	Common Stock	S	2792	$24.68	Disposed	1259718	Direct
2020-03-16	Common Stock	S	6704	$25.85	Disposed	1253014	Direct
2020-03-16	Common Stock	S	9370	$26.74	Disposed	1243644	Direct
2020-03-16	Common Stock	S	1134	$27.39	Disposed	1242510	Direct

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.19 to $25.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.23 to $26.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.24 to $27.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.25 to $27.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.